Safety and Complications Reporting Update on the Re-Implantation of Culture-Expanded Mesenchymal Stem Cells Using Autologous Platelet Lysate Technique

Centeno, Christopher J.; Schultz, John R.; Cheever, Michelle; Freeman, Michael; Faulkner, Stephen J.; Robinson, Brent; Hanson, Ronald D.

doi:10.2174/157488811797904371

Cited by 153 publications

(84 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, the question whether these cells are safe for clinical application is heavily discussed in the current literature [63,64,65]. …”

Section: Current Gaps and Controversies: Tumorigenesismentioning

confidence: 99%

“…Consequently, the treatment with ADSCs in cancer diseases is not recommended as, in contrary, it could have dramatic side effects. These studies should not be ignored when considering clinical application of human ADSCs for regenerative therapies, even if no malignant behavior of MSCs has been reported in clinical studies so far [65]. …”

Section: Current Gaps and Controversies: Tumorigenesismentioning

confidence: 99%

See 1 more Smart Citation

Adipose Tissue-Derived Stem Cells in Regenerative Medicine

Frese

Dijkman

Hoerstrup

2016

Transfus Med Hemother

346

245

View full text Add to dashboard Cite

In regenerative medicine, adult stem cells are the most promising cell types for cell-based therapies. As a new source for multipotent stem cells, human adipose tissue has been introduced. These so called adipose tissue-derived stem cells (ADSCs) are considered to be ideal for application in regenerative therapies. Their main advantage over mesenchymal stem cells derived from other sources, e.g. from bone marrow, is that they can be easily and repeatable harvested using minimally invasive techniques with low morbidity. ADSCs are multipotent and can differentiate into various cell types of the tri-germ lineages, including e.g. osteocytes, adipocytes, neural cells, vascular endothelial cells, cardiomyocytes, pancreatic β-cells, and hepatocytes. Interestingly, ADSCs are characterized by immunosuppressive properties and low immunogenicity. Their secretion of trophic factors enforces the therapeutic and regenerative outcome in a wide range of applications. Taken together, these particular attributes of ADSCs make them highly relevant for clinical applications. Consequently, the therapeutic potential of ADSCs is enormous. Therefore, this review will provide a brief overview of the possible therapeutic applications of ADSCs with regard to their differentiation potential into the tri-germ lineages. Moreover, the relevant advancements made in the field, regulatory aspects as well as other challenges and obstacles will be highlighted.

show abstract

“…Therefore, the question whether these cells are safe for clinical application is heavily discussed in the current literature [63,64,65]. …”

Section: Current Gaps and Controversies: Tumorigenesismentioning

confidence: 99%

Section: Current Gaps and Controversies: Tumorigenesismentioning

confidence: 99%

Adipose Tissue-Derived Stem Cells in Regenerative Medicine

Frese

Dijkman

Hoerstrup

2016

Transfus Med Hemother

346

245

View full text Add to dashboard Cite

show abstract

“…Based on this differentiation potential, these cells have been used to treat patients in various orthopedic conditions. Centeno et al [99] reported the results of 339 patients having received autologous bone marrow-derived MSC expanded in autologous HPL. Adverse event surveillance revealed a few cases most probably related to the re-implant procedure and three cases possibly related to stem cell applications.…”

Section: Platelet Lysatementioning

confidence: 99%

Platelet Lysate as Replacement for Fetal Bovine Serum in Mesenchymal Stromal Cell Cultures

Bieback

2013

Transfus Med Hemother

178

180

View full text Add to dashboard Cite

Mesenchymal stromal cells (MSC) emerged as highly attractive in cell-based regenerative medicine. Initially thought to provide cells capable of differentiation towards mesenchymal cell types (osteoblasts, chondrocytes, adipocytes etc.), by and by potent immunoregulatory and pro-regenerative activities have been discovered, broadening the field of potential applications from bone and cartilage regeneration to wound healing and treatment of autoimmune diseases. Due to the limited frequency in most tissue sources, ex vivo expansion of MSC is required compliant with good manufacturing practice (GMP) guidelines to yield clinically relevant cell doses. Though, still most manufacturing protocols use fetal bovine serum (FBS) as cell culture supplement to isolate and to expand MSC. However, the high lot-to-lot variability as well as risk of contamination and immunization call for xenogenic-free culture conditions. In terms of standardization, chemically defined media appear as the ultimate achievement. Since these media need to maintain all key cellular and therapy-relevant features of MSC, the development of chemically defined media is still - albeit highly investigated - only in its beginning. The current alternatives to FBS rely on human blood-derived components: plasma, serum, umbilical cord blood serum, and platelet derivatives like platelet lysate. Focusing on quality aspects, the latter will be addressed within this review.

show abstract

“…Bay-Jensen et al [85] recently reported a link between cartilage disease and metabolic syndrome, suggesting that patient deficiency in either estrogen or thyroid hormone may be an initiator, driver, or both of OA. Studies have evaluated the overall safety and complication rates of BMC therapy in orthopedic applications with encouraging outcomes [86,87]. Hendrich et al [86] studied BMC, concluding that on-site preparation of BMC eliminates ex vivo cell proliferation and is safer in the use of autologous cell therapy.…”

Section: Safety Considerations With Bmc Therapymentioning

confidence: 99%